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Psychosocial Aspects of Glaucoma
Ashutosh Dayal
Abstract
Glaucoma, not only leads to irreversible visual impairment, but also has a 
negative impact on Quality of Life of the patients. Visual disability, lifelong medi-
cal and surgical treatments and even the mere knowledge of having an irreversible 
potentially blinding condition tend to cause severe psychological stress in patients, 
leading to negative emotions such as anxiety or depression. The goal of glaucoma 
treatment should not be limited to preserving the vision, but also address the 
psychological aspects and preservation of patient wellbeing. Patient counselling, 
right from at the time of diagnosis, periodic psychological assessment and creat-
ing awareness in the society as a whole should be implemented as a part of holistic 
approach to glaucoma. Utilisation of Patient- reported quality of life tools would 
help clinicians in more closely understanding the problems and would, in turn, aid 
in providing comprehensive customised treatment option for each patient.
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1. Introduction
Glaucoma is a chronic progressive optic nerve disease that can potentially lead 
to blindness, if left untreated. It is the second most common cause of blindness 
and the leading cause of irreversible blindness worldwide [1]. Global prevalence 
of glaucoma has been estimated to be 3.54%, though geographic variations exist. 
Incidence of Primary open angle glaucoma has been found to be highest in African 
countries, while that of primary angle closure glaucoma in Asian populations 
[2]. Presently, 80 million people are affected with glaucoma, worldwide. This 
number is expected to rise to almost 111 million by the year 2040 [2, 3]. However, 
these numbers may just be reflecting the tip of the iceberg. Owing to slow and 
silent progression, the disease remains undiagnosed in many individuals till fairly 
advanced stages. Diagnosis is often delayed and approximately 40% of retinal 
nerve fibres are lost by the time field defects could be appreciated on standard 
White-on-White perimetry [4]. Moreover, the disease characteristically involves 
peripheral and mid peripheral visual fields initially, which may go unnoticed in 
many patients. Elderly population is at a greater risk as they tend to ignore it as an 
age-related inevitability [5]. Unfortunately, at the time of first presentation, most 
patients have significant irreversible peripheral visual field defects. This is truer 
for population residing in developing and underdeveloped countries, with less 
awareness and limited access to basic eyecare services. Some of the earlier epide-
miologic studies conducted in West Indies, [6] Australia [7] and Netherlands [8] 
reported more than 50% patients having undiagnosed glaucoma during screening. 
Data from Indian studies reported an even higher proportion of undiagnosed 
cases discovered during screening [9–11].
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World health organisation (WHO) has defined Quality of life as “individuals 
perception of their position in life in the context of the culture and value systems in 
which they live and in relation to their goals, expectations, standards and concerns.” 
[12]. In other words, it can be defined as an individual’s own measure of various life 
conditions experienced by him, including physical health, mental and psychologi-
cal health, dependency, social functioning and economic wellbeing. Thus, condi-
tions affecting any or all of the above-mentioned aspects, would hamper Quality of 
life. Glaucoma not only causes permanent visual disability, but also has a negative 
influence on mental and psychological health, which is subjective and individual 
specific [5]. Individuals with glaucoma tend to develop negative emotions such as 
anxiety or depression, which are detrimental in the daily functioning and wellbe-
ing. With the number of glaucoma cases projected to rise, the psychosocial aspect of 
glaucoma is now becoming a global concern for clinicians all over.
2. Factors affecting quality of life in glaucoma
2.1 Disability due to visual field defects
Glaucoma causes irreversible defects in the visual fields, that are slow and pro-
gressive. Glaucomatous visual field defects appear to be non-specific and follow the 
pattern of retinal nerve fibre layer loss [13]. Initially, the disease involves peripheral 
fields and tends to go unnoticed, till the time it progresses to involve central and 
paracentral areas. Hence, it is less common for an individual with early glaucoma 
to present with visual symptoms. Although, some individuals, particularly those 
involved in driving or sports, may notice these peripheral field defects rather early. 
Typically, by the time a patient presents with visual symptoms, significant field 
defects have already set in. With progression of the disease, patients find it more 
and more difficult to pursue day to day activities. They find themselves bumping 
into objects while walking, as they are unable to perceive obstacles in the path which 
lie in the non-seeing areas of the visual field. In advance stages, blindness ensues 
causing complete dependency even for performing routine tasks. Studies have 
demonstrated that beside visual fields, glaucoma also affects other visual functions 
such as contrast sensitivity and dark adaptation. Impairment of these functions can 
further compound the problems for the patients. Activities such as night time driv-
ing, that require good peripheral vision with dark adaptation and contrast sensitiv-
ity, become difficult to execute. All these factors cause significant visual disability 
among patients, even in moderate stages of the disease. Difficulty in carrying out 
daily activities and fear of falling increases dependency and limits social function-
ing [14]. This causes a negative effect on patients’ thought process, and directly 
impacts their mental health. It is evident through various studies, that deterioration 
of Quality of life and mental health status is associated with the worsening of visual 
impairment in glaucoma [15–17].
2.2 Adverse effect related to treatment
Intraocular pressure is the only known modifiable risk factor known for glau-
coma [18]. Hence the current treatment options aim at reducing the intraocular 
pressure. This can be achieved either by medications, laser treatment or filtration 
surgeries. Conventionally medical management, by the use of topical or systemic 
intraocular pressure lowering agents, is considered as the first line therapy. 
Monotherapy with one agent or a combination of two or more agents may be 
required to achieve the target intraocular pressure, depending on the severity of 
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disease. Here we briefly discuss some of the commonly prescribed topical medica-
tion and related adverse effects:
Prostaglandin Analogues (e.g., Latanoprost, Bimatoprost, Travoprost): 
Preferred as first line agents in glaucoma patients. They lower the intraocular 
pressure most effectively, with once daily dosing, by facilitating the uveoscleral 
outflow. Prostaglandin analogues do have several associated ocular side effects 
including darkening of iris colour, trichomegaly (eyelash growth), periocular skin 
pigmentation, conjunctival hyperaemia and cystoid macular edema.
Beta adrenergic blockers (e.g., Timolol, Betaxolol, Levobunolol): One of 
the most commonly used drugs as first line therapy. It reduces the production 
of aqueous humour by acting on the ciliary body, inhibiting beta adrenergic 
receptors. Effects may be lost in time due to tachyphylaxis. In addition, it can be 
associated with local and systemic side effects such as bradycardia, bronchospasm, 
hypoglycaemia, depression, dry eye, punctate keratitis. Ocular stinginess is 
associated with betaxolol.
Alpha adrenergic receptor agonist (e.g.: Brimonidine): It is potent class of 
antiglaucoma agents used as first line therapy. It is recommended mainly for 
chronic use in patients with concomitant cardiopulmonary disease or any other 
contraindications to beta-blockers. Adverse effects include allergic conjunctivitis, 
conjunctival hyperaemia, pruritis, dry eye, fatigue and drowsiness.
Carbonic Anhydrase inhibitor (e.g.: Dorzolamide, Brinzolamide): It is 
derivative of sulphonamide, which decreases the production of aqueous humour. 
After corneal penetration, it inhibits the carbonic anhydrase in the ciliary 
body, slowing local bicarbonate production which in turn decreases sodium 
and fluid transport, thus reducing aqueous humour secretion. It can precipitate 
corneal edema with patients with decompensated cornea. Other ocular adverse 
effects include stinging sensation, metallic taste in mouth after instillation and 
granulomatous anterior uveitis (rare).
All the topical agents have potential to cause localised ocular adverse effects that 
can cause discomfort to the patient. Moreover, many of the intraocular pressure low-
ering agents require more than once daily dosing schedule, that elderly patients might 
find tedious or difficult to follow. Apart from the ocular and systemic effects of the 
topical medications, problems associated with preservatives present in the prepara-
tions, on ocular surface, should be borne in mind. Preservatives are additive agents 
added to extend the shelf-life of an ophthalmic preparation. Commonly used pre-
servatives include Benzalkonium chloride (BAK), Purite, parabens, chlorobutanol, 
sodium chlorite, and a boric acid plus D-sorbitol plus zinc chloride fixed combina-
tion. However, these preservative agents are known to destabilise the cell membrane, 
causing cell loss and reduced cell surface adhesions, in normal corneal and conjunc-
tival tissue. This may give rise to various ocular surface diseases, including superficial 
punctate keratitis with corneal erosions, papillary conjunctivitis, dry eye, low tear 
film break-up time, conjunctival injection and anterior chamber inflammation.
Treatment for glaucoma requires lifelong instillation of intraocular pressure 
lowering medications. Chronic instillation of these medications over a period of 
time can accentuate insult to the ocular surface. Recent studies have demonstrated 
cellular level changes, including epithelial thickening, loss of goblet cells and 
conjunctival stromal thickening, associated with long term use of antiglaucoma 
medications [19]. With altered ocular surface structure, the tear film function gets 
compromised resulting in conditions such as dry eye syndrome and conjunctivitis 
medicamentosa. Prevalence of ocular surface disease has been estimated to be 59% 
in patients with glaucoma, with medication playing a significant part [20]. Ocular 
surface disease was found to have a negative impact on patient reported quality of 
life scores, with majority reporting ocular pain and discomfort [16, 21]. Although 
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preservative free preparations are now available in the market, which claim to be 
free from adverse effects of preservatives, further studies would be required to 
conclusively prove their superiority over the conventional preparations.
On the other hand, surgical interventions such as trabeculectomy or drainage 
device implant, though reduce the dependency on topical medications, come with 
their own disadvantages. These include intraocular pressure fluctuations, lifelong 
follow ups, need for secondary interventions such as antimetabolite injections, 
bleb needling or repeat surgery in case of filtration failure. Patients with surgical 
intervention reported more ocular discomfort, probably owing to the presence of 
conjunctival bleb on the ocular surface [22].
2.3 Psychological impact of diagnosis of glaucoma
As with other chronic diseases, diagnosis of glaucoma can be a stressful experi-
ence and a psychological burden for the patient. Even on just learning about the 
diagnosis, many patients develop negative emotions such as anxiety or depression. 
Given the potential blinding nature of the disease, bulk of the negative thoughts 
arise due to the fear of going blind. Moreover, factors such as changes in daily 
routine, regular use of medications, lifelong treatment and follow ups can cause 
psychological stress. Studies done in recent decades have provided us with an 
insight into the patient thought process. In the Collaborative Initial Glaucoma treat-
ment study, the newly diagnosed patients were found to have moderate to severe 
psychological fear of blindness at the time of diagnosis [23]. Odberg et al. reported 
negative emotions in almost 90% of newly diagnosed cases of glaucoma [24]. This 
psychological stress may be partly attributed to lack of awareness about the disease 
in general population. Patients tend to misinterpret the diagnosis of glaucoma as 
that of impending blindness. They are totally unaware of the treatment options 
available, and the fact that the disease progression can be retarded or halted with 
the use of various medical and surgical modalities. Poor disease comprehension has 
shown to be negatively associated with psychological and quality of life scores [25]. 
It should be borne in mind that patients can develop psychological emotions such as 
anxiety and fear of potential outcomes irrespective of duration of disease.
2.4 Financial and economic perspectives
Glaucoma, being a chronic disease, can become a financial burden for the 
patients. Cumulative cost of treatment over many years- whether medical or 
surgical- can be a major problem for patients. A significant proportion of patients 
reside in middle to low-income countries, with low per capita income and lack of 
government funded social security schemes, affordability of treatment may be a 
challenge for them in the long run. These patients have to spend a large share of 
their monthly income on treatment for glaucoma. A single follow up visit to the 
hospital leads to financial loss to those employed as daily wage workers. For people 
residing in remote areas with inadequate health facilities, even travelling all the way 
for a follow-up visit is a herculean task. All these factors play a significant role in 
patients not adhering to treatment and follow-ups. As the disease progresses and 
visual fields deteriorate, patients find themselves at a constant risk of loss of liveli-
hood. With loss of livelihood, and limited or no other sources of income, continuing 
treatment of glaucoma becomes virtually impossible.
Hence it is evident that glaucoma associated psychosocial impairment is mul-
tifactorial, and not just caused by loss of visual function alone. Psychological and 
financial factors play an equal role in determining the quality of life of a patient. 
In recent decades, much attention has been drawn towards assessment of the 
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psychological effects of glaucoma, in an attempt to preserve social wellbeing of 
the patients. Population based cross sectional studies have been conducted in both 
developed as well as developing and underdeveloped regions. Studies conducted in 
Singapore, [26] China, [25] Japan, [17] India, [15, 16] Germany [27] and Nigeria 
[28] have brought forth the conclusion that glaucoma does have a deleterious effect 
on patient psychology, mental health status, social functioning and above all quality 
of life. The quality of life of deteriorates as the disease progresses, owing to worsen-
ing of visual fields, limitation of social functioning and increased dependency. 
Significant prevalence of anxiety and depression in patients with glaucoma reflects 
the enormous psychological burden of the disease [26, 27].
3. Management- what needs to be done?
Earlier, management for glaucoma was aimed only at preserving the visual 
function by control of intraocular pressure. Less emphasis was given to psychologi-
cal impact of the disease as well as its implication on quality of life of the patients. 
Today, with the data from various studies, we now know the mental, social, finan-
cial and psychological implications of the disease. Considering the prevalence of 
glaucoma, the magnitude of problem is tremendous. Hence, mere treatment of 
raised intraocular pressure may not be sufficient. One should aim at providing a 
decent quality of life and preserving patient wellbeing. It should be borne in mind 
that one should treat the patient and not just intraocular pressure.
3.1 Patient counselling
It has been demonstrated that disease comprehension is often poor among 
patients, causing psychological stress and feeling of despair and panic. Counselling of 
patients about the disease can help alleviate this problem to some extent. Counselling 
should be started right at the time of diagnosis, by the treating clinician and contin-
ued on periodic basis over the course of treatment. Patients should be made aware 
about the disease, treatment options available for them, importance of treatment 
compliance and periodic follow-up. This would help in alleviation the psychological 
fear, as shown by Odberg et al. in their study [24]. During the course of treatment, 
patients may require periodic motivation to adhere to the treatment and follow ups.
3.2 Assessment of psychological state and quality of life
A qualitative or quantitative assessment of psychological state of the patient 
should be included as a part of glaucoma management. This can be performed with 
the use of various tools in the form questionnaires. Some of the commonly avail-
able tools are mentioned in Table 1. These questionnaires can be either generic 
(Short Form-36) or vision specific (NEIVFQ-51, NEIVFQ-25) or disease specific 
(Glaucoma Quality of Life −15, Glaucoma symptom scale). Although any of the 
above-mentioned tools can be utilised as per convenience, Patient reported outcomes 
(PRO) have been more commonly used tools. PRO based questionnaires provide a 
better perspective of the difficulties experienced by the patient. Apart from quality 
of life, separate instruments are available for measuring negative mental conditions- 
precisely anxiety and depression. Some of the tools such as Hospital Anxiety and 
Depression scale (HADS), General Anxiety Disorder-7 (GAD-7) are easy to use and 
can be self-administered in the clinic or at home. As with counselling, such assess-
ment should be done at the time of diagnosis and periodically during follow ups. Any 
deterioration in the scores would warrant need for intervention such as counselling. 
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It should be kept in mind that individuals with poor quality of life scores or negative 
emotions are susceptible to treatment non-compliance. Hence it is essential that the 
treating clinicians remain aware of the psychological condition of their patients.
3.3 Vocational training
Visual disability becomes profound as the disease progresses to advanced stages. 
Apart from causing limitations in social functioning, it can lead to loss of livelihood. 
This may be detrimental to patient’s quality of life causing low self-esteem and frustra-
tion. In such scenarios, vocational training and use of low vision aid devices can be 
beneficial for many patients. Use of low vision devices such as magnifiers, telescopes 
or field expanders can help patients in utilising their residual field of vision. Vocational 
training activities would help them with performing routine tasks independently. 
Moreover, they can learn newer skills that may generate livelihood opportunities for 
some. These activities can provide patients with much needed self-confidence, reduce 
dependency and would aid in improving Quality of life to some extent.
3.4 Creating awareness among general population
With constant rise in number of people with glaucoma, there is a need to create 
awareness about the disease among the masses. Sensitising the community regard-
ing the disease, its treatment as well as about the problems faced by the patients 
would help in generating community- based support for patients with glaucoma. 
Such moral support from friends and family members would be beneficial for the 
patients in keeping themselves motivated while facing the challenges associated 
with glaucoma. Community based social groups for persons with glaucoma should 
be promoted, wherein patients can share their experiences and problems.
4. Conclusion
Patients with glaucoma are prone for developing psychological disturbances that 
in tun negatively affect quality of life. Apart from visual disability, psychological 
Name of questionnaire Brief Description




25 -item questionnaire measuring vision dependent functioning and influence 
of vision problems on quality of life. Measures various patient reported 
functions including general health, mental health, social health, dependency, 
driving, near vision, colour vision, ocular pain etc. All these sub scores are used 
to calculate composite score.
It measures Patient reported outcomes (PRO)
Glaucoma Quality of Life 
−15 (GQL-15)
It’s a disease specific questionnaire. Assesses only vision related difficulty, 
taking into account the effect of binocular visual field loss on visual function.
Short Form-36 (SF 36) Short general health questionnaire.
Assesses the physical component, mental health, emotional- role and social 
functioning.




It is the shorter version of the original 100 item questionnaire.
Measures General health, positive feeling, social support, financial resources/
physical, psychological and social relationships
Table 1. 
Brief description of some commonly used validates questionnaires for assessment of quality of life.
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effect of diagnosis, treatment related adverse effects and financial issues play 
an important role in hampering the quality of life. A comprehensive approach 
consisting of patient education, psychological assessment, motivational counselling 
and vocational therapy should be adopted as a part of glaucoma management 
protocol. This would enable clinicians to provide customised holistic treatment for 
each patient, thereby increasing compliance and providing better quality of life.
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